:Monotherapy for serious bacterial infections (including Pseudomonas) and anaerobes.
:Efficacy rate (95.5%) in the treatment of moderate and severe intra-abdominal infections.
:Only approved carbapenem for the treatment of pediatric bacterial meningitis.
:First-line treatment of febrile episodes in neutropenic patients
:Product manufactured by Fresenius Kabi in Europe.
One clear glass vial in a carton box
:indicated for the treatment of following infections in adults and children over 3 months of age:
Pneumonias and nosocomial pneumonias
Urinary tract infections
Intra-abdominal infections
Gynaecological infections such as endometritis and pelvic inflammatory disease
Bacterial Meningitis
Septicaemia
Empiric treatment for presumed infections in patient with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents. Meropenem IV has proved efficacious alone or in combination with other antimicrobial agents in the treatment of poly microbial infections
:The recommended dose for intravenous infusion is 0.5 gm to 2 gm (10 to 40 mg/kg) by slow infusion , 3 times per day.
:For Children (3 months to 12 years old) , the usual dose is 10 mg – 40 mg per kg for every 8 hours. If body weight > 50 kg, same as adult dose.
:Meropenem can be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 – 30 minutes.
: Renal impairment : The dose for adults should be adjusted when creatinine clearance is less than 51 ml/min.
:Hepatic insufficiency : No dose adjustment is necessary in patient with hepatic insufficiency.
:Elderly : No dose adjustment is requried for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
